PUNE: The much-awaited national rollout zydus cadillaof covid Vaccination, ZyCoV-DIt’s going to take two more weeks.
“Various batches of ZyCoV-D are undergoing the final round of quality checks at the Vaccine Testing Laboratory in Himachal Pradesh. If everything goes according to plan, the vaccine will be introduced in the vaccination schedule by October 15-20. NK Arora, Chairman of the Center’s COVID Working Group on the National Technical Advisory Group on Immunization (NTAGI), told TOI on Sunday.
The three-dose needle-free ZyCoV-D vaccine, manufactured by Ahmedabad-based Zydus Cadila, is the first vaccine in India to have received emergency use authorization (one of the European Union) to be administered to persons 12 years of age and above.
The vaccine is based on plasmid DNA technology and follows a three-dose regimen with an interval of 28 days between each dose. “Since it is a three-dose vaccine, we need to ensure availability of one crore doses every month for the next one. Three months,” Arora said. Developed in partnership with the Department of Biotechnology, ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of SARS-CoV-2 to elicit an immune response. It is an intradermal vaccine that must be administered using a ‘needle-free injector’, which the manufacturer says will help reduce side effects.
“Various batches of ZyCoV-D are undergoing the final round of quality checks at the Vaccine Testing Laboratory in Himachal Pradesh. If everything goes according to plan, the vaccine will be introduced in the vaccination schedule by October 15-20. NK Arora, Chairman of the Center’s COVID Working Group on the National Technical Advisory Group on Immunization (NTAGI), told TOI on Sunday.
The three-dose needle-free ZyCoV-D vaccine, manufactured by Ahmedabad-based Zydus Cadila, is the first vaccine in India to have received emergency use authorization (one of the European Union) to be administered to persons 12 years of age and above.
The vaccine is based on plasmid DNA technology and follows a three-dose regimen with an interval of 28 days between each dose. “Since it is a three-dose vaccine, we need to ensure availability of one crore doses every month for the next one. Three months,” Arora said. Developed in partnership with the Department of Biotechnology, ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of SARS-CoV-2 to elicit an immune response. It is an intradermal vaccine that must be administered using a ‘needle-free injector’, which the manufacturer says will help reduce side effects.
.